This SRS strategy is being validated in an ongoing phase II clinical trial (NCT02314364) among oncogene-addicted (EGFR-, ALK-, ROS1-positive) NSCLC patients with up to four BM. Here, ALK is linked to non-small cell lung carcinoma.